Newsfeeds - Spark Newswire

2 minute read

Gilead’s Kite Reports Collaboration Deal With Appia Bio To Research, Develop Allogeneic Cell Therapies For Cancer

Today, 9:36 PM

Kite, a Gilead Company (NASDAQ:GILD), and Appia Bio, Inc., an early stage biotechnology company developing engineered allogeneic cell therapies from hematopoietic stem cells (HSCs) for cancer patients, today announced a

GILD

2 minute read

Movers

Unusual Options Activity Insight: Gilead Sciences

By Benzinga Insights

Today, 9:36 PM

Shares of Gilead Sciences (NASDAQ:GILD) saw some unusual options activity on Wednesday. Following the unusual option alert, the stock price moved down to $69.45.

GILD

6 minute read

The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam’s Clinical Collaboration, 4 IPOs

By Shanthi Rexaline

Today, 9:36 PM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29)

ABBV

1 minute read

SVB Leerink Maintains Outperform on Gilead Sciences, Raises Price Target to $77

By Benzinga Newsdesk

Today, 9:36 PM

SVB Leerink analyst Geoffrey Porges maintains Gilead Sciences (NASDAQ:GILD) with a Outperform and raises the price target from $74 to $77.

GILD

22 minute read

Earnings Scheduled For July 29, 2021

By Benzinga Insights

Today, 9:36 PM

Companies Reporting Before The Bell • Smith & Nephew (NYSE:SNN) is projected to report earnings for its second quarter.

1 minute read

Gilead Ordered To Pay Attorney Fees In Shareholder Lawsuit

By Sam Corey

Today, 9:36 PM

Gilead Sciences Inc. (NYSE: GILD) was ordered to pay about $1.8 million late last week in attorney’s fees and legal expenses to shareholders who sued the company after they were blocked from reviewing notable company records, according to

GILD

5 minute read

The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer’s Conference, IPOs and More

By Shanthi Rexaline

Today, 9:36 PM

Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start to the pharma reporting season.

ABBV

2 minute read

Understanding Gilead Sciences’s Unusual Options Activity

By Benzinga Insights

Today, 9:36 PM

Shares of Gilead Sciences (NASDAQ:GILD) saw some unusual options activity on Tuesday. Following the unusual option alert, the stock price moved up to $69.14.

GILD

1 minute read

BioNTech Snaps Up Solid Tumor TCR Platform, Manufacturing Site From Gilead For Undisclosed Sum

By Vandana Singh

Today, 9:36 PM

BioNTech SE (NASDAQ:BNTX) is buying a cell therapy R&D platform plus a manufacturing site from Gilead Science Inc’s (NASDAQ:GILD) Kite subsidiary. The deal…

BNTX

3 minute read

Uncategorized

BioNTech To Acquire Kite’s Neoantigen TCR Cell Therapy R&D Platform And Manufacturing Facility In Gaithersburg, MD; Financial Terms Not Disclosed

By Bill Haddad

Today, 9:36 PM

Deal strengthens BioNTech's cell therapy pipeline by accelerating individualized solid tumor Neoantigen TCR cell therapy research and development program and adding manufacturing footprint in North America Kite

BNTX